We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

113 hedge funds and large institutions have $612M invested in ARS Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

528% more call options, than puts

Call options by funds: $6.42M | Put options by funds: $1.02M

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

70% more capital invested

Capital invested by funds: $359M → $612M (+$253M)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

33% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 27

13% more funds holding

Funds holding: 100 → 113 (+13)

6.2% less ownership

Funds ownership: 68.26% → 62.06% (-6.2%)

Holders
113
Holders Change
+13
Holders Change %
+13%
% of All Funds
1.63%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
27
Increased
36
Reduced
27
Closed
14
Calls
$6.42M
Puts
$1.02M
Net Calls
+$5.4M
Net Calls Change
+$3.76M

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$10.4M
2
State Street
State Street
Massachusetts
+$7.66M
3
PA
Perceptive Advisors
New York
+$6.47M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$5.82M
5
Invesco
Invesco
Georgia
+$2.96M

Top Sellers

Rank Fund Capital Flow
1
CST
Charles Schwab Trust
Nevada
-$21.9M
2
BBA
Baker Bros. Advisors
New York
-$11M
3
NCM
Nantahala Capital Management
Connecticut
-$8.75M
4
Franklin Resources
Franklin Resources
California
-$8.56M
5
KPF
K2 Principal Fund
Ontario, Canada
-$6.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
26
Sectoral Asset Management
Quebec, Canada
$2.09M -$1.12M -150,204 -42%
GCP
27
GSA Capital Partners
United Kingdom
$1.32M +$101K +13,545 +12%
Wellington Management Group
28
Wellington Management Group
Massachusetts
$1.16M +$844K +113,205 New
Citadel Advisors
29
Citadel Advisors
Florida
$1.15M +$598K +80,262 +252%
Rafferty Asset Management
30
Rafferty Asset Management
New York
$1.14M +$832K +111,559 New
UBS Group
31
UBS Group
Switzerland
$1.07M +$766K +102,713 +5,944%
AIC
32
AWM Investment Company
New York
$1.02M +$746K +100,000 New
Morgan Stanley
33
Morgan Stanley
New York
$1M -$879K -117,873 -55%
N
34
Nuveen
North Carolina
$997K – – –
Citigroup
35
Citigroup
New York
$996K +$688K +92,223 +1,760%
Jane Street
36
Jane Street
New York
$944K +$31K +4,163 +5%
Bank of America
37
Bank of America
North Carolina
$834K -$127K -17,019 -17%
American Century Companies
38
American Century Companies
Missouri
$828K +$243K +32,593 +67%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$826K -$1.29M -172,571 -68%
Arrowstreet Capital
40
Arrowstreet Capital
Massachusetts
$826K +$602K +80,798 New
Capstone Investment Advisors
41
Capstone Investment Advisors
New York
$739K +$539K +72,322 New
Bank of New York Mellon
42
Bank of New York Mellon
New York
$714K -$108K -14,467 -17%
AA
43
ALPS Advisors
Colorado
$692K +$9.78K +1,312 +2%
Swiss National Bank
44
Swiss National Bank
Switzerland
$675K – – –
Wealth Enhancement Advisory Services
45
Wealth Enhancement Advisory Services
Minnesota
$652K +$37 +5 +0%
FWP
46
FAS Wealth Partners
Kansas
$618K +$108K +14,500 +32%
AllianceBernstein
47
AllianceBernstein
Tennessee
$605K -$27K -3,620 -6%
LCS
48
Levin Capital Strategies
New York
$565K +$22.4K +3,000 +6%
JP Morgan Chase
49
JP Morgan Chase
New York
$513K +$116K +15,534 +45%
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$423K +$79.2K +10,619 +34%
1
2
3 4 5

SPRY Hedge Fund Activity: Q1 2024 in Review

113 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2024, worth a combined $612M — up 70% from $359M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new SPRY positions and 14 closed out — a net gain of 13 holders — while 36 added to existing stakes and 27 trimmed.

The largest buyer was RA Capital Management, adding an estimated $10.4M. The largest seller was Charles Schwab Trust, exiting entirely with an estimated $21.9M sold.

  • 113 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2024, up from 100 in Q4 2023.
  • Funds reported $612M of ARS Pharmaceuticals stock for Q1 2024, up 70% quarter-over-quarter.
  • 27 funds opened new ARS Pharmaceuticals positions in Q1 2024 and 14 closed out, a net change of +13 holders.
  • The largest ARS Pharmaceuticals buyer in Q1 2024 was RA Capital Management, an estimated $10.4M added.
  • The largest ARS Pharmaceuticals seller in Q1 2024 was Charles Schwab Trust, an estimated $21.9M sold.

Based on aggregated 13F filings for Q1 2024.